Post-radical prostatectomy management options for positive surgical margins : Argument for observationMOUL, Judd W.Urologic oncology. 2009, Vol 27, Num 1, pp 92-96, issn 1078-1439, 5 p.Conference Paper

Variables in predicting survival based on treating PSA-Only relapseMOUL, Judd W.Urologic oncology. 2003, Vol 21, Num 4, pp 292-304, issn 1078-1439, 13 p.Article

Treatment of PSA only recurrence of prostate cancer after prior local therapy : New therapies in prostate cancer: Controlling metastatic disease and preventing oncogenesisMOUL, Judd W.Current pharmaceutical design. 2006, Vol 12, Num 7, pp 785-798, issn 1381-6128, 14 p.Article

Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trialsMOUL, Judd W.Urology (Ridgewood, NJ). 2001, Vol 57, Num 4A, pp 174-177, issn 0090-4295Article

Focusing on TestosteroneMOUL, Judd W; DREICER, Robert.Urology (Ridgewood, NJ). 2011, Vol 78, Num 5A, issn 0090-4295, S476-S477, SUPConference Paper

New Data, New Paradigms for Treating Prostate Cancer PatientsDREICER, Robert; MOUL, Judd W.Urology (Ridgewood, NJ). 2011, Vol 78, Num 5A, issn 0090-4295, 26 p., SUPConference Proceedings

Contralateral testicular biopsy procedure in patients with unilateral testis cancer: Is it indicated?HEIDENREICH, Axel; MOUL, Judd W.Seminars in urologic oncology. 2002, Vol 20, Num 4, pp 234-238, issn 1081-0943, 5 p.Article

Emerging Treatment Options for Patients With Castration-Resistant Prostate CancerGEORGE, Daniel; MOUL, Judd W.The Prostate. 2012, Vol 72, Num 3, pp 338-349, issn 0270-4137, 12 p.Article

Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapyMOUL, Judd W; ZLOTTA, Alexandre R.BJU international (Papier). 2005, Vol 95, Num 3, pp 285-290, issn 1464-4096, 6 p.Article

New Data, New Paradigms for Treating Prostate Cancer Patients—VI: Novel Hormonal Therapy ApproachesDREICER, Robert; BAJORIN, Dean F; MCLEOD, David G et al.Urology (Ridgewood, NJ). 2011, Vol 78, Num 5A, issn 0090-4295, S494-S498, SUPConference Paper

Targeting the Androgen Receptor—Theory and PracticeDREICER, Robert; GLEAVE, Martin; KIBEL, Adam S et al.Urology (Ridgewood, NJ). 2011, Vol 78, Num 5A, issn 0090-4295, S482-S484, SUPConference Paper

Indications and Practice With Androgen Deprivation TherapyMOUL, Judd W; KIBEL, Adam S; ROACH, Mack et al.Urology (Ridgewood, NJ). 2011, Vol 78, Num 5A, issn 0090-4295, S478-S481, SUPConference Paper

Traditional Approaches to Androgen Deprivation TherapyMOUL, Judd W; EVANS, Christopher P; GOMELLA, Leonard G et al.Urology (Ridgewood, NJ). 2011, Vol 78, Num 5A, issn 0090-4295, S485-S493, SUPConference Paper

Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003MOUL, Judd W; FOWLER, Jackson E.Urology (Ridgewood, NJ). 2003, Vol 62, Num 6A, pp 20-28, issn 0090-4295, 9 p.Conference Paper

The changing face of prostate cancerCOOPERBERG, Matthew R; MOUL, Judd W; CARROLL, Peter R et al.Journal of clinical oncology. 2005, Vol 23, Num 32, pp 8146-8151, issn 0732-183X, 6 p.Article

Management of the patient with a rising PSA aloneMOUL, Judd W; WARD, John F.Hematology/oncology clinics of North America. 2006, Vol 20, Num 4, issn 0889-8588, ix, 897-908 [13 p.]Article

The role of imaging studies and molecular markers for selecting candidates for radical prostatectomyMOUL, Judd W; KANE, Christopher J; MALKOWICZ, S. Bruce et al.Urologic clinics of North America. 2001, Vol 28, Num 3, issn 0094-0143, vii, 459-472 [15 p.]Article

A Framework to Evaluate the Cost-Effectiveness of the NADiA ProsVue Slope to Guide Adjuvant Radiotherapy among Men with High-Risk Characteristics Following Prostatectomy for Prostate CancerREED, Shelby D; STEWART, Suzanne Biehn; SCALES, Charles D et al.Value in health. 2014, Vol 17, Num 5, pp 545-554, issn 1098-3015, 10 p.Article

Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancerCASO, Jorge R; TSIVIAN, Matvey; MOURAVIEV, Vladimir et al.BJU international (Papier). 2010, Vol 106, Num 11, pp 1623-1627, issn 1464-4096, 5 p.Article

Prostate-Specific Antigen Screening Among Young Men in the United StatesSCALES, Charles D; ANTONELLI, Jodi; CURTIS, Lesley H et al.Cancer. 2008, Vol 113, Num 6, pp 1315-1323, issn 0008-543X, 9 p.Article

Screening for prostate cancer in high risk populations. Commentary. Authors' replyCATALONA, William J; ANTENOR, Jo Ann V; ROEHL, Kimberly A et al.The Journal of urology. 2002, Vol 168, Num 5, pp 1980-1984, issn 0022-5347Article

Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapyAL BAHA BARQAWI; MOUL, Judd W; ZIADA, Ali et al.Urology (Ridgewood, NJ). 2003, Vol 62, Num 5, pp 872-876, issn 0090-4295, 5 p.Article

Baseline Prostate-Specific Antigen Testing at a Young AgeLOEB, Stacy; CARTER, H. Ballentine; CATALONA, William J et al.European urology. 2012, Vol 61, Num 1, pp 1-7, issn 0302-2838, 7 p.Article

Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-AmericansCAIRE, Arthur A; LEON SUN; POLASCIK, Thomas J et al.BJU international (Papier). 2010, Vol 106, Num 8, pp 1157-1160, issn 1464-4096, 4 p.Article

Radical perineal prostatectomy for the treatment of localized prostate cancer in morbidly obese patientsDAHM, Philipp; YANG, Benjamin K; SALMEN, Chas R et al.The Journal of urology. 2005, Vol 174, Num 1, pp 131-134, issn 0022-5347, 4 p.Article